MYND Life Sciences (TSE:MYND) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
MYND Life Sciences plans to issue 4 million shares to eliminate $3.5 million in debt, including restructuring an outstanding debenture, to enhance shareholder value and focus on developing their biomarker test for depression. This strategic financial move aims to strengthen MYND’s position and accelerate the development of a potentially groundbreaking diagnostic tool for major depressive disorder.
For further insights into TSE:MYND stock, check out TipRanks’ Stock Analysis page.